Hospira has announced the introduction of Sapphire infusion system, a next-generation portable pump, following regulatory clearance from the US Food and Drug Administration (FDA).
It features a full-colour touchscreen and software designed to enable intuitive programming and operation with minimal steps.
The smart pump capabilities of the Sapphire system help healthcare organisations support a high-level of medication delivery safety.
In addition, the Sapphire infusion system helps simplify patient care across diverse clinical areas through its flexible infusion modes.
Sapphire is reportedly the first touchscreen ambulatory infusion pump platform available for use in hospital, ambulatory and home care settings.
Hospira Medication Management Systems vice-president Rich Nevin said launching the Sapphire infusion pump to company’s US customers demonstrates its commitment to improving medication delivery and strengthens the breadth of its medication management business.
"The Sapphire system was developed to easily adapt to changing clinical needs and allows Hospira to provide clinicians with the most up-to-date device technology," Nevin said.
The company has rolled out Sapphire system as a replacement for its retired GemStar ambulatory pumps as a lightweight compact infusion option.
It represents a major step in the advancement of the company’s global device strategy as indicated earlier in May 2013.
The Sapphire platform forms an important addition to Hospira’s streamlined and modernised US device portfolio; it is already available in Europe and Canada.
Q Core Medical CEO Dr Boaz Eitan said: "This is yet another successful stage in the international cooperation between the companies, and we believe that the combination of our technology with Hospira’s excellent customer support and in-depth experience in the US market will begin a new era in infusion solutions for our customers."
In January 2013, Hospira and Q Core Medical have entered into a distribution agreement for the Q Core Sapphire multi-therapy infusion system.
The agreement grants Hospira the exclusive rights to market and distribute Sapphire in more than 60 key markets across Europe, Asia and The Americas.
The deal also enables Hospira to collaborate with Q Core for distribution of its product development pipeline.
Hospira’s current portfolio features products such as Plum A+ with Hospira MedNet safety software, a proven and scalable advanced infusion pump system and LifeCare PCA pain management pump with Hospira MedNet.
According to GlobalData estimates, the infusion systems market in the US was valued at $2.68bn in 2012 and is expected to grow at a CAGR of 3.5% to reach $3.41bn by 2019.
